β-blockers in the treatment of periocular infantile hemangioma

Al‐Haddad, Christiane; Salloukh, Nasrine Anais El; Moussawi, Zeinab El

doi:10.1097/icu.0000000000000591

Cited by 29 publications

(35 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ariwibowo, Danarti et al and associates found that Timolol maleate 0.5% the answer was better than corticosteroids in reducing the dimensions of superficial IH. 10,14,[17][18][19][20][21][22][23][24] Our study also showed reduction in size,colour and shape of superficial infantile hemangiomas in approximately 08-12 weeks after the initiation of treatment.…”

Section: A H E a D O F P R I N Tsupporting

confidence: 68%

Role of topical beta blockers in regression of infantile capillary hemangioma

Junejo

Rebecca²,

Memon³

et al. 2021

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To observe efficacy of Timolol maleate 0.5% by topical and surface application in infantile superficial capillary hemangioma of eyelid. Methods: This multi-centered clinical case series was carried out at Ophthalmology Department of Bilawal Medical College and Institute of Ophthalmology, LUMHS, Jamshoro from November 2019 to May 2020. We included 14 subjects. All the patients were subjected to detailed clinical examination. Before starting the topical beta blockers, the enrolled subjects had obtained the expert opinion by pediatrician to rule out any preexisting developmental cardio vascular disease. Topical beta blockers 0.5% drops were thus started with, against the ongoing finding of superficial capillary hemangioma of eyelid. Results: There was significant regression in size of infantile hemangioma after treating with topical timolol maleate 0.5%. We included 14 subjects in this study. Mean±SD age of patients was 4.94. Complete regression was seen in 08 subjects at the end of 12 weeks (64%) while 03 were completely cured at 08 weeks (21%) and 01 patient lost follow up with us. No significant ocular and systemic side effects were noted. Conclusion: Topical timolol maleate 0.5% can be the first-line treatment modality for superficial capillary hemangiomas due to its better safety and efficacy. doi: https://doi.org/10.12669/pjms.37.7.4317 How to cite this:Junejo MS, Rebecca, Memon MN, Shaikh SP. Role of topical beta blockers in regression of infantile capillary hemangioma. Pak J Med Sci. 2021;37(7):---------. doi: https://doi.org/10.12669/pjms.37.7.4317 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: A H E a D O F P R I N Tsupporting

confidence: 68%

Role of topical beta blockers in regression of infantile capillary hemangioma

Junejo

Rebecca²,

Memon³

et al. 2021

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…Besides, drugs belonging to beta-blockers (timolol and propranolol) are registered to treat hemangiomas in newborns. Topical administration is relatively well tolerated and has few side effects while maintaining a high therapeutic response [ 19 , 20 ]. The use of beta-blockers in topical administration allows for use in the treatment of glaucoma [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Chitosan as Valuable Excipient for Oral and Topical Carvedilol Delivery Systems

Sip

Paczkowska-Walendowska

Rosiak

et al. 2021

Pharmaceuticals

View full text Add to dashboard Cite

Chitosan is a valued excipient due to its biocompatibility properties and increasing solubility of poorly water-soluble drugs. The research presented in this paper concerns the preparation of binary combinations of chitosan (deacetylated chitin) with carvedilol (beta-blocker) to develop a formulation with a modified carvedilol release profile. As part of the research, six physical mixtures of chitosan with carvedilol were obtained and identified by spectral (PXRD, FT-IR, and Raman), thermal (DSC), and microscopic (SEM) methods. The next stage of the research estimated the profile changes and the dissolution rate for carvedilol in the obtained drug delivery systems; the reference sample was pure carvedilol. The studies were conducted at pH = 1.2 and 6.8, simulating the gastrointestinal tract conditions. Quantitative changes of carvedilol were determined using the developed isocratic UHPLC-DAD method. Established apparent permeability coefficients proved the changes in carvedilol’s permeability after introducing a drug delivery system through membranes simulating the gastrointestinal tract and skin walls. A bioadhesive potential of carvedilol–chitosan systems was confirmed using the in vitro model. The conducted research and the obtained results indicate a significant potential of using chitosan as an excipient in modern oral or epidermal drug delivery systems of carvedilol.

show abstract

“…The mechanism by which beta-blockers involute the hemangioma is unknown, and it is possible that a combination of both effects is accountable for the treatment of IH. 2 , 3…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies revealed that complete involution of IH was found in 50% by the age of 5 years, 70% by the age of 7 years, and 90% by the age of 9 years. 2 , 3…”

mentioning

confidence: 99%

Oral Beta-blocker in Problematic Infantile Hemangioma

AlHasan¹,

Arabiyat

Ammar³

et al. 2021

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Summary: One of the most common benign vascular endothelial tumors is infantile hemangioma. These lesions are commonly found in the head and neck, and sometimes it is a challenge to decide the method of treatment if the lesions are problematic hemangiomas, interfering with function or aesthetic appearance. This study reports a case of girl aged 3 years, 7 months, diagnosed with periorbital infantile hemangioma that was successfully treated with oral propranolol in specific doses and gradual tapering off dose. The patient had marked involution of the lesion with no significant side effects after starting her treatment at the age of 4 months, for a total of 13 months with no reported rebound growth after almost 2 years since the termination of treatment. Oral beta-blockers can be used safely in treatment of problematic infantile hemangioma as a single modality, without any surgical intervention.

show abstract

β-blockers in the treatment of periocular infantile hemangioma

Cited by 29 publications

References 65 publications

Role of topical beta blockers in regression of infantile capillary hemangioma

Role of topical beta blockers in regression of infantile capillary hemangioma

Chitosan as Valuable Excipient for Oral and Topical Carvedilol Delivery Systems

Oral Beta-blocker in Problematic Infantile Hemangioma

Contact Info

Product

Resources

About